The Future of Device Biologics
This timely presentation by AnneMarie Moseley, CEO, Aggregate Therapeutics, explores the impact of the converging medical device and biologic industries on the development of regenerative medicine products.
By assessing the influence of combination product regulations on both biologic and device products, it provides a necessary focus on the timeliness and cost of device-biologic development and engineering.
Through the use of specific industry case studies, gain insight into considerations for evaluating investment in convergent regenerative medicine technologies and strategies for minimizing the overall risk profile.
Watch This Presentation (in new window).
Annemarie Moseley MD PhD has extensive background in stem cell commercialization and product development as CEO or Senior Executive with several biopharmaceutical and device companies.
Prior to becoming Acting CEO of Aggregate Therapeutics, Dr. Moseley was Fellow, Clinical and Regulatory Affairs Group of Guidant Corporation. Previously, she was founding CEO of Cognate Therapeutics, a startup cellular therapy company developing bone marrow stromal cells and other stem cell technologies. Prior to this, Dr. Moseley was the CEO of Osiris Therapeutics, Inc. an adult mesenchymal stem cell company. While she was at Osiris, the company led the stem cell development field with five new INDs in multiple therapeutic areas.
Dr. Moseley has been involved in development of biological products such as antibodies, gene and cell therapies for over 12 years with companies such as AIS/Aventis and Systemix/Novartis. She is currently also a Director of Repair Technologies, a biotech startup in the San Francisco area focused on endogenous repair of tissue injury.
Discussion
No comments for “The Future of Device Biologics”
Post a comment